|
Pulmatrix Announces Presentation of Clinical Data Demonstrating iCALM Inhaled …
MarketWatch (press release) "We are strongly committed to advancing a pipeline of iCALM therapies to treat chronic respiratory diseases, including COPD, asthma and cystic fibrosis." "iCALM's ability to limit allergen-induced eosinophilic airway inflammation in this trial is … |
View full post on asthma – Google News